About

Dr. Ari Kellen is an experienced senior executive with over three decades of healthcare industry experience. After practicing medicine and running a large segment of the Johannesburg Hospital in South Africa, Dr. Kellen was recruited to McKinsey & Company where he spent 22 years as a strategic advisor to boards of directors and CEOs of major health care clients across the globe.

In 2014 Dr. Kellen was recruited to Valeant Pharmaceuticals. Running US Bausch + Lomb, R&D, Latin America and Dermatology, he helped lead the company through a challenging period involving a change in leadership and business strategy, and was subsequently promoted by the new CEO and Board to the global segment leader of Bausch + Lomb.

Since 2017 Dr. Kellen has been serving as a strategic advisor and investor to early-stage innovative healthcare companies in the US, Europe, and Israel. He serves on the boards of Theraclion and Vaxil Bio, and is a strategic advisor to several other companies including BioNanoSim and Nouri Life. Dr Kellen is a graduate of the University of the Witwatersrand in South Africa where he received his Medical and MBA degrees with distinction.